• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

June 4, 2018
Company Drug/Device Medical Condition Status
NeoImmune Tech, Inc. HyLeukin-7 brain cancer Phase I trial initiated enrolling up to 75 subjects
Atox Bio Reltecimod Abdominal sepsis and Stage 2/3 Acute Kidney Injury (AKI) Phase II trial initiated enrolling 120 subjects at approximately 50 level 1 trauma centers in the U.S.
Atox Bio Reltecimod Necrotizing Soft Tissue Infections (NSTI) Phase III trial initiated enrolling 290 subjects at approximately 70 level 1 trauma sites in the U.S.
Synedgen Catasyn Advanced Technology Wound Hydrogel wound care 510(k) clearance granted by the FDA
Novartis Promacta (eltrombopag) Severe aplastic anemia (SAA) sNDA approval granted by the FDA
Nektar Therapeutics NKTR-181 chronic lower back pain NDA approval granted by the FDA
Sage Therapeutics brexanolone (SAGE-547) postpartum depression (PPD) NDA approval granted by the FDA
MicroVention, Inc. Low profile Visualized Intraluminal Support (LVIS) and LVIS Jr. neuro stent devices wide-necked saccular intracranial aneurysms PMA granted by the FDA
Dova Pharmaceuticals Doptelet (avatrombopag) thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure Approval granted by the FDA
TherapeuticsMD Imvexxy (TX-004HR) moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), symptom of vulvar and vaginal atrophy (VVA) Approval granted by the FDA
BioMarin Pharmaceutical Palynziq (pegvaliase-pqpz) Henylketonuria (PKU) Approval granted by the FDA
Zeto, Inc. zEEG dry electrode electroencephalography (EEG) headset Approval granted by the FDA
Astellas Pharma Inc. gilteritinib Relapsed or refractory Acute Myeloid Leukemia (AML) with a FLT3 mutation Priority Review granted by the FDA
Pfizer Xalkori (crizotinib) Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy Breakthrough Therapy Designation granted by the FDA
Pfizer tafamidis Transthyretin cardiomyopathy Breakthrough Therapy Designation granted by the FDA
Yamo Pharmaceuticals, LLC L1-79 autism spectrum disorder (ASD) Fast Track Designation granted by the FDA
Genea Biocells GBC0905 Facioscapulohumeral muscular dystrophy (FSHD) Orphan Drug Designation granted by the FDA

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing